Avalyn Pharma Inc. Common Stock (AVLN)
Усі метрики
Порівняння з галуззю — Фармацевтика(311)
| Символ | P/S (TTM) | Зростання виручки TTM (р/р) | Валова маржа (TTM) | Зростання EPS (5 років) | Ціна |
|---|---|---|---|---|---|
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | $27.33 |
| LLYEli Lilly & Co. | 12.36x | 47.44% | 82.83% | 27.59% | $948.45 |
| JNJJohnson & Johnson | 5.53x | 7.87% | 67.95% | 14.90% | $221.32 |
| ABBVABBVIE INC. | 5.83x | 8.57% | 71.62% | -2.88% | $201.55 |
| MRKMerck & Co., Inc. | 4.18x | 2.89% | 78.07% | 21.23% | $111.38 |
| NVONovo-Nordisk A/S | 4.25x | 6.43% | 80.98% | 20.66% | $46.07 |
| NVSNovartis AG | 4.74x | 5.77% | 75.41% | 15.26% | $146.03 |
| AZNAstraZeneca PLC | 4.66x | 9.93% | 81.42% | 21.88% | $182.85 |
| ABTAbbott Laboratories | 3.25x | 6.59% | 56.50% | 8.20% | $84.32 |
| PFEPfizer Inc. | 2.31x | 1.36% | 74.80% | -3.51% | $25.68 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | 2.48x | 4.41% | 52.77% | — | $35.73 |
Про акцію
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.